Shares of Soleno Therapeutics (SLNO) jumped 9.1% on Tuesday and continued to gain another 4.1% during the after-market hours following a positive regulatory update on its new drug application (NDA) seeking approval for DCCR (diazoxide choline) extended-release tablets to treat Prader-Willi syndrome (PWS). Per SLNO, the Review Division of the FDA has stated that there is no need for an advisory committee meeting for the DCCR NDA at present. However, the regulatory body will continue to consider the potential ...